DRIO Quote, Financials, Valuation and Earnings

Forian, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of -1.95%. DarioHealth Corp.'s return on equity of -41.55% beat Forian, Inc.'s return on equity of -2.86%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 81.77%. On the other hand Forian, Inc. has an analysts' consensus of $2.10 which suggests that it could fall by -0.47%. Given that DarioHealth Corp. has higher upside potential than Forian, Inc., analysts believe DarioHealth Corp. is more attractive than Forian, Inc..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison Forian, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Forian, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Forian, Inc. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than Forian, Inc. quarterly revenues of $7.8M. DarioHealth Corp.'s net income of -$2.1M is lower than Forian, Inc.'s net income of -$151.2K. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Forian, Inc.'s PE ratio is 49.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 5.57x versus 2.34x for Forian, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GoodRx Holdings, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 0.57%. DarioHealth Corp.'s return on equity of -41.55% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 81.77%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $4.88 which suggests that it could grow by 76.29%. Given that DarioHealth Corp. has higher upside potential than GoodRx Holdings, Inc., analysts believe DarioHealth Corp. is more attractive than GoodRx Holdings, Inc..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. DarioHealth Corp.'s net income of -$2.1M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 32.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 5.57x versus 1.27x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 11.54%. DarioHealth Corp.'s return on equity of -41.55% beat National Research Corp.'s return on equity of 61.55%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 81.77%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth Corp. has higher upside potential than National Research Corp., analysts believe DarioHealth Corp. is more attractive than National Research Corp..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.55% to investors and pays a quarterly dividend of $0.12 per share. DarioHealth Corp. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than National Research Corp. quarterly revenues of $34.6M. DarioHealth Corp.'s net income of -$2.1M is lower than National Research Corp.'s net income of $4M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 26.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 5.57x versus 3.08x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 9.46%. DarioHealth Corp.'s return on equity of -41.55% beat Spok Holdings, Inc.'s return on equity of 10.88%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 81.77%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.17%. Given that DarioHealth Corp. has higher upside potential than Spok Holdings, Inc., analysts believe DarioHealth Corp. is more attractive than Spok Holdings, Inc..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.59% to investors and pays a quarterly dividend of $0.31 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. DarioHealth Corp.'s net income of -$2.1M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 5.57x versus 1.94x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.